Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency.
Por:
Marin-Bejar O, Romero-Moya D, Rodriguez-Ubreva J, Distefano-Muñoz ME, Lessi F, Aretini P, Liquori A, Castaño J, Kozyra E, Kotmayer L, Bueno C, Cervera J, Rodriguez-Gallego JC, Nomdedeu JF, Murillo-Sanjuán L, De Heredia CD, Pérez-Martinez A, López-Cadenas F, Martínez-Laperche C, Dorado-Herrero N, Marco FM, Prósper F, Menendez P, Valcárcel D, Ballestar E, Bödör C, Bigas A, Català-Temprano A, Wlodarski MW and Giorgetti A
Publicada:
1 sep 2023
Ahead of Print:
1 sep 2023
Categoría:
Hematology
Resumen:
Filiaciones:
Marin-Bejar O:
Regenerative Medicine Program, Bellvitge Institute for Biomedical Research (IDIBELL) and Program for Clinical Translation of Regenerative Medicine in Catalonia (P-CMRC), Barcelona.
Romero-Moya D:
Regenerative Medicine Program, Bellvitge Institute for Biomedical Research (IDIBELL) and Program for Clinical Translation of Regenerative Medicine in Catalonia (P-CMRC), Barcelona
Rodriguez-Ubreva J:
Epigenetics and Immune Disease Group, Josep Carreras Research Institute (IJC), Barcelona
Distefano-Muñoz ME:
Department of Hematology and Oncology, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona
Lessi F:
Fondazione Pisana Per la Scienza ONLUS (FPS), San Giuliano Terme
Aretini P:
Fondazione Pisana Per la Scienza ONLUS (FPS), San Giuliano Terme
Liquori A:
Hematology Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain
Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Instituto de Salud Carlos III, Madrid
Castaño J:
Advanced and Cell Therapy Services. Banc de Sang i Teixits, Barcelona
Kozyra E:
Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine
Faculty of Biology, University of Freiburg, Freiburg
Kotmayer L:
HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University. Budapest, Hungary
Bueno C:
Josep Carreras Leukaemia Research Institute. Department of Biomedicine. School of Medicine, University of Barcelona, Barcelona
Cervera J:
Hematology Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain
Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
Genetics Unit, Hospital Universitario y Politécnico La Fe, Valencia
Rodriguez-Gallego JC:
Department of Immunology, University Hospital of Gran Canaria Dr. Negrín, Canarian Health System, Las Palmas de Gran Canaria, Spain
Department of Clinical Sciences, University Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain
Department of Medical and Surgical Sciences, School of Medicine, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria
Nomdedeu JF:
Servei d'Hematologia Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, IIB Sant Pau/Josep Carreras Leukaemia Research Institute (IJC), Barcelona
Murillo-Sanjuán L:
Pediatric Hematology and Oncology Division, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Barcelona
De Heredia CD:
Pediatric Hematology and Oncology Division, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Barcelona
Pérez-Martinez A:
Pediatric Department, Universidad Autonoma de Madrid, Madrid, Spain
Hospital La Paz Institute for Health Research, Madrid, Spain
Pediatric Hemato-Oncology Department, University Hospital La Paz, Madrid
López-Cadenas F:
Servicio de Hematología Hospital Clínico Universitario de Salamanca, salamanca, Spain
Instituto Biosanitario de Salamanca (IBSAL). Salamanca
Martínez-Laperche C:
Servicio de Hematología, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid
Dorado-Herrero N:
Servicio de Hematología, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid
Marco FM:
Immunology Department, Dr. Balmis General University Hospital
Institute for Health and Biomedical Research (ISABIAL), Alicante
Prósper F:
Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
Area de Hemato-Oncología, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain
Servicio de Hematologia, CCUN, Clínica Universidad de Navarra, Universidad de Navarra, Pamplona
Menendez P:
Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
Josep Carreras Leukaemia Research Institute. Department of Biomedicine. School of Medicine, University of Barcelona, Barcelona, Spain
Red Española de Terapias Avanzadas (TERAV) - Instituto de Salud Carlos III, Madrid, Spain
Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona
Valcárcel D:
Servei d'Hematologia, Vall d'Hebron Hospital Universitari
Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO)
Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona
Ballestar E:
Epigenetics and Immune Disease Group, Josep Carreras Research Institute (IJC), Barcelona, Spain
Epigenetics in Inflammatory and Metabolic Diseases Laboratory, Health Science Center (HSC), East China Normal University (ECNU), Shanghai
Bödör C:
HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University. Budapest, Hungary
Bigas A:
Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
Programa de Investigación en Cáncer, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
Josep Carreras Leukaemia Research Institute (IJC), Barcelona
Català-Temprano A:
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid
Department of Hematology and Oncology, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Deu, Barcelona, Spain
Wlodarski MW:
Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN
Giorgetti A:
Regenerative Medicine Program, Bellvitge Institute for Biomedical Research (IDIBELL) and Program for Clinical Translation of Regenerative Medicine in Catalonia (P-CMRC), Barcelona, Spain
Fondazione Pisana Per la Scienza ONLUS (FPS), San Giuliano Terme, Italy
Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Barcelona University, Barcelona.
Green Submitted, gold
|